Precede Consortium Incorporated is located in Red Hook, NY. According to its NTEE Classification (T22) the organization is classified as: Private Independent Foundations, under the broad grouping of Philanthropy, Voluntarism & Grantmaking Foundations and related organizations. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. Precede Consortium Incorporated is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.
For the year ending 12/2022, Precede Consortium Incorporated generated $833.1k in total revenue. This represents a relatively dramatic decline in revenue. Over the past 2 years, the organization has seen revenues fall by an average of (15.9%) each year. All expenses for the organization totaled $799.6k during the year ending 12/2022. You can explore the organizations financials more deeply in the financial statements section below.
Form
990PF
Mission & Program ActivityExcerpts From the 990PF Filing
TAX YEAR
2022
Describe the Organization's Program Activity:
Part 3 - Line 4a
BUILDING A POPULATION-BASED FAMILIAL COHORT OF INDIVIDUALS WHO ARE AT HIGH-RISK OF DEVELOPING PANCREATIC CANCER. IN PARTNERSHIP ARBOR RESEARCH, PRECEDE OVER THE NEXT 5 YEARS WILL BE FORMING A CONSORTIUM OF CANCER CENTERS FROM AROUND THE WORLD TO DEVELOP AND MAINTAIN A COMMON DATABASE ON THE ARBORLINK PLATFORM, INCLUDING CLINICAL AND FAMILY HISTORY INFORMATION, AS WELL AS CATALOGUING AND TRACKING OF BIOLOGICAL SAMPLES AND IMAGING DATA. THE SCIENTIFIC GOAL OF THE CONSORTIUM INCLUDES (1) IMPROVING RISK MODELING FOR PANCREATIC CANCER, BASED ON THE GENETIC AND ENVIRONMENTAL RISK FACTORS, (2) DEVELOPING A VALIDATION COHORT FOR AN EARLY DETECTION TEST FOR PANCREATIC CANCER, (3) TESTING THE CONCEPT THAT SCREENING IN THIS POPULATION WILL SAVES LIVES, (4) PERFORMING CLINICAL TRIALS USING THE EARLY DETECTION TEST.
Name (title) | Role | Hours | Compensation |
---|---|---|---|
Diane Simeone MD P. Investigator | 5 | $0 | |
Jessica Everett Ms Cgc Genetic Counsel | 5 | $0 | |
Fay Kastrinos MD P. Investigator | 5 | $0 | |
Aimee Lucas MD Ms P. Investigator | 5 | $0 | |
George Zogopoulos MD PHD P. Investigator | 5 | $0 | |
Randall Brand MD P. Investigator | 5 | $0 |
Statement of Revenue | |
---|---|
Contributions, Gifts, Grants & Similar | $833,146 |
Interest on Savings | $0 |
Dividends & Interest | $0 |
Net Rental Income | $0 |
Net Gain on Sale of Assets | $0 |
Capital Gain Net Income | $0 |
Net ST Capital Gain | $0 |
Income Modifications | $0 |
Profit on Inventory Sales | $0 |
Other Income | $0 |
Total Revenue | $833,146 |
Statement of Expenses | |
---|---|
Compensation of officers, directors, trustees, etc | $0 |
Other employee salaries and wages | $0 |
Pension plans, employee benefits | $0 |
Interest | $0 |
Taxes | $0 |
Depreciation | $0 |
Occupancy | $0 |
Travel, conferences, and meetings | $35,181 |
Printing and publications | $0 |
Other expenses | $705,352 |
Total operating and administrative expenses | $799,566 |
Contributions, gifts, grants paid | $0 |
Total expenses and disbursements | $799,566 |
Balance Sheet | |
---|---|
Cash—non-interest-bearing | $912,527 |
Savings and temporary cash investments | $0 |
Net Accounts receivable | $0 |
Net Pledges Receivable | $0 |
Grants receivable | $0 |
Receivables from Officers, Directors, or Controlling Persons | $0 |
Net other notes and loans receivable | $0 |
Inventories for sale or use | $0 |
Prepaid expenses and deferred charges | $0 |
Net Investments - land, buildings, equipment | $0 |
Investments—mortgage loans | $0 |
Investments—other | $0 |
Net Land, buildings, and equipment | $0 |
Other assets | $0 |
Total assets | $912,527 |
Accounts payable and accrued expenses | $0 |
Grants payable | $0 |
Deferred revenue | $0 |
Loans and other payables to any current Officer, Director, or Controlling Person | $0 |
Mortgages and other notes payable | $0 |
Other liabilities | $0 |
Total liabilities | $0 |